Akari Therapeutics (AKTX) Short Interest Ratio & Short Volume

Short interest is the volume of Akari Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 10,500 shares of AKTX short. 0.16% of Akari Therapeutics' shares are currently sold short. Learn More on Akari Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKTX shares currently have a short interest ratio of 1.0. Learn More on Akari Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.16% of Akari Therapeutics' floating shares are currently sold short.

Akari Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 10,500 shares, an increase of 75.0% from the previous total of 6,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Akari Therapeutics currently has issued a total of 7,920,000 shares. Some of Akari Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Akari Therapeutics currently has a public float of 6,590,000 shares.

0.16% of Akari Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Akari Therapeutics: Biofrontera Inc. (0.95%), Galera Therapeutics, Inc. (4.07%), Adial Pharmaceuticals, Inc. (0.24%), Molecular Templates, Inc. (1.15%), Longeveron Inc. (3.10%), Hepion Pharmaceuticals, Inc. (1.47%), Aeterna Zentaris Inc. (0.45%), Alterity Therapeutics Limited (0.28%), Moleculin Biotech, Inc. (2.09%), Virios Therapeutics, Inc. (1.13%),

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

Short selling AKTX is an investing strategy that aims to generate trading profit from Akari Therapeutics as its price is falling. AKTX shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Akari Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AKTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKTX, twice per month. The most recent reporting period available is March, 31 2024.